49020 Federal Register / Vol. 74, No. 185 / Friday, September 25, 2009 / Notices 

Against Women Recovery Act 

solicitation template. 

The Department of Justice (DOJ), 

Office of Justice Programs will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

The proposed information collection is 

published to obtain comments from the 

public and affected agencies. This 

proposed information collection was 

previously published in the Federal 

Register Volume 74, Number 140, page 

36510, on July 23, 2009. Comments are 

encouraged and will be accepted for 

thirty days until October 26, 2009. This 

process is conducted in accordance with 

5 CFR 1320.10. 

If you have additional comments, 

especially on the estimated public 

burden or associated response time, 

suggestions, or need a copy of the 

proposed information collection 

instrument with instructions or 

additional information, please contact: 

Amy Callaghan, (202) 514–9292, Office 

of Audit, Assessment, and Management, 

Office of Justice Programs, Department 

of Justice, 810 Seventh Street, NW., 

Washington, DC 20531 or 

Amy.Callaghan@usdoj.gov. 

Written comments and suggestions 

from the public and affected parties 

concerning the proposed collection of 

information are encouraged. Your 

comments should address one or more 

of the following four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information will have 

practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Enhance the quality, utility, and 

clarity of the information to be 

collected; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of this information: 

(1) Type of information collection: 

Information in response to the required 

data elements outlined in the 

solicitation template for programs 

funded under the American Recovery 

and Reinvestment Act of 2009. 

(2) The title of the form/collection: 

Office of Justice Programs and the Office 

on Violence Against Women Recovery 

Act solicitation template. 

(3) The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

The form label is OMB No. 1121–0323. 

The Office of Audit, Assessment, and 

Management, Office of Justice Programs, 

U.S. Department of Justice is sponsoring 

the collection. 

(4) Affected public who will be asked 

or required to respond, as well as a brief 

abstract: State agencies, tribal 

governments, local governments, 

colleges and universities, non-profit 

organizations, for-profit organizations 

and faith-based organizations. The 

purpose of the Recovery Act solicitation 

template is to provide a framework to 

develop program-specific 

announcements soliciting applications 

for funding. A program solicitation 

outlines the specifics of the funding 

program; describes requirements for 

eligibility; instructs an applicant on the 

necessary components of an application 

under a specific program (e.g, project 

activities and timeline, proposed 

budget); and provides registration dates, 

due dates, and instructions on how to 

apply within the designated application 

system. 

(5) An estimate of the total number of 

respondents and the amount of time 

estimated for an average respondent to 

respond/reply: It is estimated that 

information will be collected annually 

from 250 applicants, representing State 

agencies, tribal governments, local 

governments, colleges and universities, 

non-profit organizations, and for-profit 

organizations. Annual cost to the 

respondents is based on the number of 

hours involved in preparing and 

submitting a complete application 

package. Public reporting burden for 

this collection of information is 

estimated at up to 30 hours per 

application. The 30-hour estimate is 

based on the amount of time to prepare 

research and evaluation proposals, one 

of the most time-intensive types of 

applications solicited by OJP. The 

estimate of burden hours is based on 

OJP’s prior experience with the 

application submission process. 

(6) An estimate of the total public 

burden (in hours) associated with the 

collection: The estimated public burden 

associated with this collection is 7,500 

hours. 

If additional information is required 

contact: Ms. Lynn Bryant, Department 

Clearance Officer, United States 

Department of Justice, Justice 

Management Division, Policy and 

Planning Staff, Suite 1600, 601 D Street, 

NW., Washington, DC 20530. 

Dated: September 22, 2009. 

Lynn Bryant, 

Department Clearance Officer, PRA, U.S. 

Department of Justice. 

[FR Doc. E9–23179 Filed 9–24–09; 8:45 am] 

BILLING CODE 4410–18–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 16, 2009, 

Cerilliant Corporation, 811 Paloma 

Drive, Suite A, Round Rock, Texas 

78665–2402, made application by 

renewal to the Drug Enforcement 

Administration (DEA) as a bulk 

manufacturer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

Cathinone (1235) .......................... I 

Methcathinone (1237) .................. I 

N–Ethylamphetamine (1475) ........ I 

N,N–Dimethylamphetamine 

(1480).

I 

Aminorex (1585) ........................... I 

4–Methylaminorex (cis isomer) 

(1590).

I 

Gamma-Hydroxybutyric acid 

(2010).

I 

Methaqualone (2565) ................... I 

Alpha-ethyltryptamine (7249) ....... I 

Lysergic acid diethylamide (7315) I 

2,5–Dimethoxy-4-(n)- 

propylthiophenethylamine 

(7348).

I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Mescaline (7381) .......................... I 

3,4,5–Trimethoxyamphetamine 

(7390).

I 

4–Bromo–2,5– 

dimethoxyamphetamine (7391).

I 

4–Bromo–2,5– 

dimethoxyphenethylamine 

(7392).

I 

4–Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5–Dimethoxyamphetamine 

(7396).

I 

2,5–Dimethoxy-4- 

ethylamphetamine (7399).

I 

3,4–Methylenedioxyamphetamine 

(7400).

I 

5–Methoxy-3,4- 

methylenedioxyamphetamine 

(7401).

I 

N–Hydroxy-3,4- 

methylendioxyamphetamine 

(7402).

I 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 185 / Friday, September 25, 2009 / Notices 49021 

Drug Schedule 

3,4–Methylendioxy-Nethylamphetamine (7404).I 

3,4– 

Methylenedioxymethamphetamine (7405).

I 

4–Methoxyamphetamine (7411) ... I 

Alpha-methyltryptamine (7432) .... I 

Bufotenine (7433) ......................... I 

Diethyltryptamine (7434) .............. I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

5–Methoxy-N,Ndiisopropyltyptamine (7439).I 

N–Benzylpiperazine (7493) .......... I 

Acetyldihydrocodeine (9051) ........ I 

Benzylmorphine (9052) ................ I 

Codeine-N-oxide (9053) ............... I 

Dihydromorphine (9145) ............... I 

Heroin (9200) ............................... I 

Hydromorphinol (9301) ................. I 

Methyldihydromorphine (9304) ..... I 

Morphine-N-oxide (9307) ............. I 

Normorphine (9313) ..................... I 

Pholcodine (9314) ........................ I 

Acetylmethadol (9601) ................. I 

Allylprodine (9602) ....................... I 

Alphacetylmethadol except levoalphacetylmethadol (9603).I 

Alphameprodine (9604) ................ I 

Alphamethadol (9605) .................. I 

Betacetylmethadol (9607) ............ I 

Betameprodine (9608) .................. I 

Betamethadol (9609) .................... I 

Betaprodine (9611) ....................... I 

Hydroxypethidine (9627) .............. I 

Noracymethadol (9633) ................ I 

Norlevorphanol (9634) .................. I 

Normethadone (9635) .................. I 

Trimeperidine (9646) .................... I 

Phenomorphan (9647) ................. I 

1–Methyl-4-phenyl-4- 

propionoxypiperidine (9661).

I 

Para-Fluorofentanyl (9812) .......... I 

3–Methylfentanyl (9813) ............... I 

Alpha-Methylfentanyl (9814) ........ I 

Acetyl-alpha-methylfentanyl 

(9815).

I 

Beta-hydroxyfentanyl (9830) ........ I 

Beta-hydroxy-3-methylfentanyl 

(9831).

I 

Alpha-Methylthiofentanyl (9832) ... I 

3–Methylthiofentanyl (9833) ......... I 

Thiofentanyl (9835) ...................... I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Lisdexamfetamine (1205) ............. II 

Phenmetrazine (1631) .................. II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Glutethimide (2550) ...................... II 

Nabilone (7379) ............................ II 

1–Phenylcyclohexylamine (7460) II 

Phencyclidine (7471) .................... II 

1– 

Piperidinocyclohexanecarbonitrile (8603).

II 

Alphaprodine (9010) ..................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Oxycodone (9143) ........................ II 

Drug Schedule 

Hydromorphone (9150) ................ II 

Diphenoxylate (9170) ................... II 

Benzoylecgonine (9180) ............... II 

Ethylmorphine (9190) ................... II 

Hydrocodone (9193) ..................... II 

Levomethorphan (9210) ............... II 

Levorphanol (9220) ...................... II 

Isomethadone (9226) ................... II 

Meperidine (9230) ........................ II 

Meperidine intermediate-A (9232) II 

Meperidine intermediate-B (9233) II 

Meperidine intermediate-C (9234) II 

Methadone (9250) ........................ II 

Methadone intermediate (9254) ... II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) ................... II 

Noroxymorphone (9668) .............. II 

Racemethorphan (9732) .............. II 

Alfentanil (9737) ........................... II 

Sufentanil (9740) .......................... II 

Tapentadol (9780) ........................ II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

small quantities of the listed controlled 

substances to make reference standards 

which will be distributed to their 

customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 24, 2009. 

Dated: September 17, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–23067 Filed 9–24–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF LABOR 

Employee Benefits Security 

Administration 

Proposed Extension of Information 

Collection; Request for Public 

Comment; Notice of Special 

Enrollment 

ACTION: Notice. 

SUMMARY: The Department of Labor 

(Department), as part of its continuing 

effort to reduce paperwork and 

respondent burden, conducts a 

preclearance consultation program to 

provide the general public and Federal 

agencies with an opportunity to 

comment on proposed and continuing 

collections of information in accordance 

with the Paperwork Reduction Act of 

1995 (PRA) (44 U.S.C. 3506(c)(2)((A)). 

This program helps to ensure that the 

data the Department gathers can be 

provided in the desired format, that the 

reporting burden on the public (time 

and financial resources) is minimized, 

that the public understands the 

Department’s collection instruments, 

and that the Department can accurately 

assess the impact of collection 

requirements on respondents. 

Currently, the Employee Benefits 

Security Administration (EBSA) is 

soliciting comments concerning the 

extension of a currently approved 

collection of information arising from 

the Department’s regulation at 29 CFR 

2590.701–6, which requires a notice of 

special enrollment to be provided to 

employees who are offered an initial 

opportunity to enroll in a group health 

plan. A copy of the information 

collection request (ICR) can be obtained 

by contacting the office shown in the 

ADDRESSES section of this notice. 

DATES: Written comments must be 

submitted to the office shown in the 

ADDRESSES section of this notice on or 

before November 24, 2009. 

ADDRESSES: Interested parties are 

invited to submit written comments 

regarding the information collection 

request and burden estimates to G. 

Christopher Cosby, Office of Policy and 

Research, Employee Benefits Security 

Administration, U.S. Department of 

Labor, 200 Constitution Avenue, NW., 

Room N–5718, Washington, DC 20210, 

(202) 693–8410, FAX (202) 219–4745 

(these are not toll-free numbers). 

Comments may also be submitted 

electronically to the following Internet 

e-mail address: ebsa.opr@dol.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

Subsection (c) of 29 CFR 2590.701–6 

requires group health plans to provide 

a notice describing the plan’s special 

enrollment rules to each employee who 

is offered an initial opportunity to enroll 

in the group health plan. The special 

enrollment rules described in the notice 

of special enrollment generally provide 

enrollment rights to employees and 

their dependents in specified 

circumstances occurring after the 

employee or dependent initially 

declines to enroll in the plan. EBSA 

previously submitted an ICR concerning 


jlentini on DSKJ8SOYB1PROD with NOTICES